BG105432A - METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION - Google Patents

METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION

Info

Publication number
BG105432A
BG105432A BG105432A BG10543201A BG105432A BG 105432 A BG105432 A BG 105432A BG 105432 A BG105432 A BG 105432A BG 10543201 A BG10543201 A BG 10543201A BG 105432 A BG105432 A BG 105432A
Authority
BG
Bulgaria
Prior art keywords
inhibitor
combination
treating atherosclerosis
employing
atherosclerosis employing
Prior art date
Application number
BG105432A
Other languages
Bulgarian (bg)
English (en)
Inventor
Jeffrey Robl
Rex PARKER
Scott Biller
Haris Jamil
Bruce Jacobson
Krishna Kodukula
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22280975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG105432(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BG105432A publication Critical patent/BG105432A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
BG105432A 1998-09-17 2001-04-10 METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION BG105432A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10067798P 1998-09-17 1998-09-17
PCT/US1999/021069 WO2000015230A1 (en) 1998-09-17 1999-09-13 METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION

Publications (1)

Publication Number Publication Date
BG105432A true BG105432A (en) 2001-12-29

Family

ID=22280975

Family Applications (2)

Application Number Title Priority Date Filing Date
BG105431A BG105431A (en) 1998-09-17 2001-04-10 METHOD FOR TREATING DIABETES EMPLOYING AN Ap2 INHIBITOR AND COMBINATION
BG105432A BG105432A (en) 1998-09-17 2001-04-10 METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BG105431A BG105431A (en) 1998-09-17 2001-04-10 METHOD FOR TREATING DIABETES EMPLOYING AN Ap2 INHIBITOR AND COMBINATION

Country Status (30)

Country Link
US (1) US20020035064A1 (es)
EP (2) EP1113801A4 (es)
JP (2) JP2002524517A (es)
KR (2) KR20010079842A (es)
CN (2) CN1317970A (es)
AT (1) ATE406898T1 (es)
AU (2) AU755563B2 (es)
BG (2) BG105431A (es)
BR (2) BR9913831A (es)
CA (2) CA2344309A1 (es)
CO (2) CO5130026A1 (es)
CZ (2) CZ2001964A3 (es)
DE (1) DE69939481D1 (es)
EE (2) EE04356B1 (es)
ES (1) ES2311306T3 (es)
GE (2) GEP20033045B (es)
HU (2) HUP0104108A2 (es)
ID (2) ID27833A (es)
IL (2) IL141786A0 (es)
LT (2) LT4870B (es)
LV (2) LV12686B (es)
NO (2) NO20011352L (es)
NZ (2) NZ510207A (es)
PE (2) PE20001056A1 (es)
PL (2) PL346660A1 (es)
SK (1) SK3202001A3 (es)
TR (2) TR200100773T2 (es)
UY (2) UY25714A1 (es)
WO (2) WO2000015229A1 (es)
ZA (2) ZA200207433B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1047423B1 (en) * 1997-11-19 2006-05-10 Takeda Pharmaceutical Company Limited Novel apoptosis inhibitors
WO2000047734A1 (en) * 1999-02-12 2000-08-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
AU2005201289B2 (en) * 1999-02-12 2008-04-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
US6548529B1 (en) * 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
WO2001054694A1 (en) 2000-01-28 2001-08-02 Bristol-Myers Squibb Company Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
AU2002237664A1 (en) 2000-11-20 2002-05-27 Bristol-Myers Squibb Company Pyridone derivatives as AP2 inhibitors
EP1385549A2 (en) * 2001-03-12 2004-02-04 Novartis AG Combination of nateglinide or repaglinide with at least one further antidiabetic compound
EP1414461A4 (en) 2001-07-13 2005-10-26 Bristol Myers Squibb Co PYRAZINONE INHIBITORS OF FATTY ACID BINDING PROTEIN AND METHOD
WO2003007888A2 (en) * 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
WO2003043624A1 (en) 2001-11-16 2003-05-30 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
WO2004069158A2 (en) 2003-01-27 2004-08-19 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
US20070043512A1 (en) * 2003-03-26 2007-02-22 Michael Rolph Therapeutic and prophylactic compositions and uses therefor
WO2004096977A2 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Crystal structure of homo sapiens adipocyte lipid binding protein and uses thereof
CA2558766A1 (en) 2004-03-05 2005-09-22 The Trustees Of The University Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
BRPI0511703B8 (pt) 2004-06-04 2021-05-25 Merck Sharp & Dhome Corp composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição
SG164378A1 (en) 2005-02-17 2010-09-29 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
CN101300232A (zh) 2005-07-26 2008-11-05 默克公司 合成取代的吡唑的方法
EP1948163A2 (en) * 2005-10-18 2008-07-30 Aegerion Pharmaceuticals Methods for treating disorders associated with hyperlipidemia in a mammal
WO2007143164A1 (en) * 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
JP2012508692A (ja) * 2008-11-12 2012-04-12 シェーリング コーポレイション 脂肪酸結合タンパク質（ｆａｂｐ）の阻害薬
PT2403605E (pt) * 2009-03-05 2015-08-05 Harvard College Composições contendo um anticorpo específico de ap2 ou um seu fragmento, para serem utilizadas no tratamento de diabetes, intolerância à glicose ou resistência à insulina induzida por obesidade
JP6223376B2 (ja) * 2014-03-24 2017-11-01 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
JP6514282B2 (ja) * 2014-03-24 2019-05-15 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
EA201792388A1 (ru) 2015-04-30 2018-06-29 Президент Энд Феллоуз Оф Гарвард Колледж Анти-ap2 антитела и антигенсвязывающие фрагменты для лечения метаболических заболеваний
EA201990136A1 (ru) * 2016-06-27 2019-05-31 Президент Энд Феллоуз Оф Гарвард Колледж Соединения, применимые для лечения нарушений обмена веществ
CA3066733A1 (en) 2017-06-09 2018-12-13 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
CA3184282A1 (en) 2020-06-27 2021-12-30 Emre Koyuncu Composition of compounds that modulate cell metabolism and methods of use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2129012A1 (de) 1971-06-11 1973-01-04 Merck Patent Gmbh Azol-derivate
FR2156486A1 (en) 1971-10-22 1973-06-01 Roussel Uclaf Oxazolyl oxy or thio acetic acids - analgesics antipyretics and anti-inflammatories
JPS5612114B2 (es) 1974-06-07 1981-03-18
GB1507032A (en) 1974-08-06 1978-04-12 Serono Lab 2-thiol-4,5-diphenyloxazole s-derivatives
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
DE3817375C2 (de) 1987-05-22 1997-04-30 Squibb & Sons Inc Phosphorhaltige HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
PT95690A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados substituidos de acidos benzoilbenzo-, bifenil- e 2-oxazol-alcanoicos, uteis como inibidores de pla2 e da lipoxigenase
US5218124A (en) * 1989-10-27 1993-06-08 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
US5262540A (en) * 1989-12-20 1993-11-16 Bristol-Myers Squibb Company [2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
FR2663331B1 (fr) 1990-06-14 1994-05-06 Bellon Laboratoires Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB9019841D0 (en) * 1990-09-11 1990-10-24 Smith Kline French Lab Compounds
US5254576A (en) * 1992-04-03 1993-10-19 Bristol-Myers Squibb Company Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors
US5348969A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US5187188A (en) * 1992-04-03 1993-02-16 Bristol-Myers Squibb Company Oxazole carboxylic acid derivatives
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5362879A (en) * 1993-04-15 1994-11-08 Bristol-Myers Squibb Company 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DE4340781C3 (de) 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
CA2179399A1 (en) * 1993-12-20 1995-06-29 Kiyoshi Taniguchi 4,5-diaryloxazole derivatives
US5599770A (en) 1994-07-15 1997-02-04 Kureha Kagaku Kogyo Kabushiki Kaisha Herbicidal composition containing 2-benzyloxypyrimidine derivatives, processes for producing the derivatives and 2-benzyloxypyrimidine derivatives
BR9508468A (pt) 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
UA56992C2 (uk) 1995-05-08 2003-06-16 Фармація Енд Апджон Компані <font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
GB9600231D0 (en) 1996-01-05 1996-03-06 Foster Wheeler Petrol Dev Ltd Spacing bouy for flexible risers
AUPO134596A0 (en) 1996-08-01 1996-08-22 Jal Pastoral Co. Pty Ltd Demountable article carrier for motor vehicles
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method

Also Published As

Publication number Publication date
EE04356B1 (et) 2004-10-15
ATE406898T1 (de) 2008-09-15
PE20001047A1 (es) 2000-12-24
SK3202001A3 (en) 2002-04-04
BG105431A (en) 2001-12-29
IL141785A0 (en) 2002-03-10
US20020035064A1 (en) 2002-03-21
NZ510209A (en) 2003-07-25
ZA200207433B (en) 2003-10-27
WO2000015230A1 (en) 2000-03-23
EP1121129A4 (en) 2002-10-16
CN1317970A (zh) 2001-10-17
EP1121129B1 (en) 2008-09-03
EP1113801A4 (en) 2002-10-02
UY25714A1 (es) 2001-08-27
NO20011351L (no) 2001-05-11
LV12687B (lv) 2001-10-20
EE200100154A (et) 2002-12-16
PL346660A1 (en) 2002-02-25
ID28450A (id) 2001-05-24
CA2344300A1 (en) 2000-03-23
AU755563B2 (en) 2002-12-12
CA2344309A1 (en) 2000-03-23
LT2001023A (en) 2001-08-27
CZ2001964A3 (cs) 2002-01-16
GEP20033044B (en) 2003-08-25
ZA200207430B (en) 2003-09-16
NO20011351D0 (no) 2001-03-16
AU6143799A (en) 2000-04-03
NO20011352D0 (no) 2001-03-16
UY25713A1 (es) 2001-08-27
NO20011352L (no) 2001-05-11
ID27833A (id) 2001-04-26
TR200100774T2 (tr) 2001-12-21
KR20010075150A (ko) 2001-08-09
LT2001022A (en) 2001-08-27
NZ510207A (en) 2003-08-29
BR9913831A (pt) 2001-05-29
AU754488B2 (en) 2002-11-14
LV12687A (en) 2001-07-20
CO5130025A1 (es) 2002-02-27
PL346661A1 (en) 2002-02-25
PE20001056A1 (es) 2000-12-24
ES2311306T3 (es) 2009-02-01
BR9913833A (pt) 2001-05-29
HUP0104240A2 (hu) 2002-03-28
EE200100155A (et) 2002-08-15
LT4870B (lt) 2001-12-27
IL141786A0 (en) 2002-03-10
KR20010079842A (ko) 2001-08-22
CZ2001965A3 (cs) 2002-02-13
LV12686A (en) 2001-07-20
CN1319012A (zh) 2001-10-24
HUP0104108A2 (hu) 2002-03-28
TR200100773T2 (tr) 2001-07-23
DE69939481D1 (de) 2008-10-16
LT4871B (lt) 2001-12-27
LV12686B (lv) 2001-10-20
JP2002524517A (ja) 2002-08-06
GEP20033045B (en) 2003-08-25
JP2002524518A (ja) 2002-08-06
EP1113801A1 (en) 2001-07-11
WO2000015229A1 (en) 2000-03-23
CO5130026A1 (es) 2002-02-27
AU6387799A (en) 2000-04-03
EP1121129A1 (en) 2001-08-08

Similar Documents

Publication Publication Date Title
BG105432A (en) METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION
AU5495090A (en) Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
AU1022795A (en) Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
HK1022105A1 (en) Naringin and naringenin as 3-hydroxy-3-methylglutaryl coa(hmg-coa) reductase inhibitor
WO1996009827A3 (en) Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
CA2249446A1 (en) Irreversible inhibitors of tyrosine kinases
NL970034I1 (nl) Trans-6-2-(3- of 4-carbonamido-gesubstitueerd pyrrool-1-yl)alkyl!-4-hydroxypyran-2-on als remmers van cholesterolsynthese.
CY1994A (en) Pharmaceutical compositions of pH at least 8 comprising an HMG-CoA reductase inhibitor
NO20012317L (no) Fremgangsmåte for å behandle, forhindre og redusere risikoen for at Alzheimers sykdom oppstår ved å bruke en HMG COAreduktaseinhibitor
MY118381A (en) Statin-carboxyalkylether combinations
IL132786A0 (en) Hmg-coa reductase inhibitor preparation process
EP0461548A3 (en) Method for preventing a second heart attack employing and hmg coa reductase inhibitor
BG106918A (en) Perocess for the preparation of sodium salts of statins
MY140504A (en) Statin-mmp inhibitor combinations
AU2177701A (en) Use of hmg-coa reductase inhibitors for treating seborrhea
IT1255470B (it) Composti attivi come inibitori dell&#39;enzima hmg-coa reduttasi
AU2003204602A1 (en) Method for treating atherosclerosis employing an aP2 inhibitor and combination
SI1114021T1 (en) NEW SALTS OF HMG-CoA REDUCTASE INHIBITORS
MX9602577A (es) Tratamiento de arterioesclerosis y xantoma.
NZ501368A (en) 3Beta-27-dihydroxy-5-cholesten-7-one and its use in pharmaceutical compositions